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Abstract
 
The M88.7 T cell clone recognizes an antigen presented by HLA B
 
*
 
1302 on the melanoma
cell line M88. A cDNA encoding this antigen (NA88-A) was isolated using a library transfec-
tion approach. Analysis of the genomic gene’s sequence identified it is a processed pseudogene,
derived from a retrotranscript of mRNA coding for homeoprotein HPX42B. The 
 
NA88-A
 
gene exhibits several premature stop codons, deletions, and insertions relative to the 
 
HPX42B
 
gene. In NA88-A RNA, a short open reading frame codes for the peptide MTQGQHFLQKV
from which antigenic peptides are derived; a stop codon follows the peptide’s COOH-terminal
Val codon. Part of the HPX42B mRNA’s 3
 
9
 
 untranslated region codes for a peptide of similar
sequence (MTQGQHFSQKV). If produced, this peptide can be recognized by M88.7 T cells.
However, in HPX42B mRNA, the peptide’s COOH-terminal Val codon is followed by a Trp
codon. As a result, expression of HPX42B mRNA does not lead to antigen production. A
model is proposed for events that participated in creation of a gene coding for a melanoma an-
tigen from a pseudogene.
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Introduction
 
CTLs can recognize antigens presented by human tumor
cells. In the hope that manipulating this CTL response to
combat cancer will prove possible, a number of groups have
started to identify the antigens in question (for review see
reference 1). The results of several clinical trials of both
adoptive immunotherapy (2) and vaccination (3–5) based
on this work suggest that the effort is worthwhile.
Most of the antigens characterized to date are HLA class I
restricted and presented by melanoma cells. Many of them
are derived from normal or mutated gene products ob-
tained by classical pathways of gene expression (1). How-
ever, an increasing number of reports describe antigens re-
sulting from the use of nonclassical pathways of gene
expression, when unexpected events take place during tran-
scription, splicing, or translation (6). Thus, the NA17-A
antigen (7) is translated from a transcript obtained by activa-
tion of a cryptic promoter within intron sequences of the
 
N
 
-acetylglucosaminyltransferase-V gene. Reverse strand
transcription of a housekeeping gene gives rise to an anti-
gen recognized by CTLs on a human kidney tumor (8). In-
tron retention during splicing is responsible for generation
of some antigens from the gp100 (9) and tyrosinase-related
protein (TRP)-2 (10) genes. Use of alternative open read-
ing frames (ORFs) for translation can also create antigens, as
described for a breast and melanoma-shared antigen (11), a
 
gp75
 
TRP-1
 
 antigen (12), a renal cell carcinoma antigen de-
rived from the intestinal carboxyl esterase gene (13), and an
antigen derived from the LAGE-1 gene (14).
We describe here a new tumor antigen generating an
HLA class I–restricted CTL response against melanoma.
Surprisingly, the antigen is coded for by a processed pseudo-
gene. Expression of the “living” counterpart of the pseudo-
gene does not lead to a corresponding CTL response. This
difference between the two genes provides insights into
how a gene coding for a tumor antigen was created.
 
Materials and Methods
 
Cell Lines.
 
Melanoma cell lines (M) were established from
metastatic tumor fragments from different patients. IPC 277/5
and IGR 1/54 melanoma cell lines were gifts from C. Aubert
(INSERM U119, Marseille, France). The FM2.29 cell line was a
gift from J. Zeuthen (Danish Cancer Society Research Center,
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Copenhagen, Denmark). DAUV melanoma cell line and mouse
fibrosarcoma WEHI 164 clone 13 used for TNF assays was ob-
tained from T. Boon (Ludwig Institute for Cancer Research,
Brussels, Belgium). T cell clone M88.7 was derived from tumor
infiltrating lymphocytes of patient M88 (A
 
*
 
0201, A
 
*
 
0301,
B
 
*
 
4002, B
 
*
 
1302, Cw
 
*
 
02022, Cw
 
*
 
0602) as described previously
(15).
 
HLA Transfection in Tumor Cell Lines.
 
Cells were seeded in
96-well plates and incubated until 80% confluent before addition
of expression vector (100 ng) and Lipofectamine (0.5 
 
m
 
l) in se-
rum-free medium. After 12–15 h, the transfection mixture was
replaced with complete medium. Transfected tumor cell lines
were used for stimulation of T cell clone M88.7 36–48 h after
transfection.
 
Library Screening.
 
Poly A
 
1
 
 
 
RNA was obtained from M88
cells using the FastTrack 2.0 mRNA extraction kit (Invitrogen
Corp.). mRNA was converted to cDNA using a cDNA synthesis
kit (Stratagene Inc.). The cDNA obtained was inserted into pCI-
neo (Promega). Recombinant plasmids were electroporated into
 
Escherichia coli 
 
XL2-Blue MRF
 
9
 
 (Stratagene Inc.). For screening,
1,500 pools of 100 ampicillin-resistant bacteria per pool were
constituted. Plasmid DNA was extracted by the alkaline lysis
method from each pool (16). For genomic gene cloning, a hu-
man cosmid library (provided by A. Haunauer, IGBMC, Stras-
bourg, France) was hybridized with the 2.7-kb NA88-A cloned
cDNA. Selected regions of the positive cosmid identified were
sequenced using the Applied Biosystems 373 DNA sequencer
with the DNA sequencing Kit Dye terminator (Perkin Elmer).
 
Transfection of COS-7 Cells.
 
DEAE–dextran-chloroquine trans-
fection was as described (17). In brief, 1.5 
 
3
 
 10
 
4
 
 COS-7 cells
were transfected with 100 ng of the HLA B
 
*
 
1302 expression vec-
tor and 100 ng of a pool of the cDNA library. Transfectants were
tested after 48 h for their ability to stimulate TNF production by
T cells. One positive pool was identified, and 500 individual plas-
mids obtained from it tested for the ability to trigger T cell clone
TNF release as described for pools.
 
T Cell Stimulation Assay.
 
T cells (2.5 
 
3 
 
10
 
3
 
 per well) were
added to COS-7 cells or tumor cells 24–48 h after transfection.
Culture supernatants were harvested 6 h later and tested for TNF
content by measuring culture supernatant cytotoxicity to WEHI
164 clone 13 in a colorimetric assay (18).
 
Production of Modified cDNAs.
 
Truncated NA88-A cDNAs
were generated using standard techniques (16) and cloned into
pcDNA3 (Invitrogen Corp.) or into pCI-neo. pNA88-A Trp,
pNA88-A Ser, and pHPX42B Stop were generated using the
QuikChange™ Site-Directed Mutagenesis Kit (Stratagene Inc.).
 
Reverse Transcriptase–PCR Assays.
 
Total RNA was extracted
by the guanidinium–cesium chloride procedure (16) and used for
cDNA synthesis (19). Some samples of tumor and normal tissue
cDNA were provided by F. Brasseur (Ludwig Cancer Institute,
Brussels, Belgium). To test for genomic DNA contamination,
cDNA samples were used for PCR with primers designed to am-
plify the 
 
MAGE-1
 
 genomic gene. None of the samples used here
gave a positive result in this test. For amplification of NA88-A
cDNA, PCR assays were performed with primers 5
 
9
 
-CCT-
TGTGGTTCGAGTCCC-3
 
9
 
 and 5
 
9
 
-GGACACGGCCACAG-
GACC-3
 
9
 
 for 35 cycles (1 min at 94
 
8
 
C, 1 min at 62
 
8
 
C, and 1
min 30 s at 72
 
8
 
C). Under these conditions, primers will not am-
plify HPX42B cDNA. PCR products were size fractionated and
blotted to Hybond-N
 
1
 
 (Amersham Pharmacia Biotech) before
hybridization with the cloned NA88-A cDNA. Samples were
normalized for RNA and cDNA integrity and quantity by PCR
amplification of human 
 
b
 
-actin cDNA (19).
 
Peptide Stimulation Assays.
 
T cell clone M88.7 was stimulated
with different concentrations of peptide (Leiden University Med-
ical Center) in the presence or absence of 10 
 
m
 
g/ml brefeldin-A
(Sigma-Aldrich). For stimulation without brefeldin-A, culture
supernatants were harvested 6 h later and tested for TNF content.
For stimulation with brefeldin-A, after 6 h cells were fixed for 10
min with PBS containing 4% paraformaldehyde, washed twice,
and stored at 4
 
8
 
C. Fixed, stimulated cells were stained for cyto-
kine. In brief, cells were stained with the PE-conjugated anti–IL-2
mAb (MQ1-17H12; BD PharMingen) at a concentration of 5
 
m
 
g/ml for 30 min at room temperature. Reagent dilutions and
washes were made with PBS containing 0.1% BSA (Sigma-Aldrich)
and 0.1% saponin (Sigma-Aldrich). After staining and washes,
cells were resuspended in PBS and analyzed on a FACScan™
(Becton Dickinson).
 
Results
 
The M88.7 T Cell Clone Recognizes an Antigen Presented
by HLA B
 
*
 
1302.
 
The CD8
 
1
 
 T cell clone M88.7, isolated
from a tumor-invaded lymph node of melanoma patient M88,
has no lytic activity but is able to secrete TNF and IL-2 on
stimulation by autologous M88 melanoma cells (data not
shown). To identify the restricting molecule, a panel of 12
melanoma cell lines not recognized by M88.7 T cells was
transiently transfected with expression vectors for the dif-
ferent HLA molecules of the M88 patient. After transfec-
tion with the HLA B
 
*
 
1302 vector (pHLA B
 
*
 
1302), 6 of the
12 lines stimulated TNF release by M88.7 T cells (Fig. 1 A).
 
Identification of a cDNA Coding for the Antigen.
 
A cDNA
library was made from M88 RNA. Plasmid DNA extracted
from pools of bacterial colonies from the library was
cotransfected with pHLA B
 
*
 
1302 into COS-7 cells. After
48 h, M88.7 T cells were added and TNF production was
assayed. Plasmid pool 651 proved positive in this test (Fig.
1 B), and the individual plasmid (pNA88-A) coding for the
antigen recognized by M88.7 T cells recovered from it.
Antigenic peptide production directed by pNA88-A is not
limited to transfected COS-7 cells: an HLA B
 
*
 
1302 mela-
noma cell line not normally recognized by M88.7 T cells
became recognizable after transfection with pNA88-A
(data not shown).
The NA88-A cDNA was sequenced (EMBL/GenBank/
DDBJ accession no. AF164963). Expression of the 
 
NA88-A
 
gene was then studied by reverse transcriptase (RT)-PCR
using primers 400 and 970 (Fig. 2 A) chosen from the se-
quence. All six melanoma cell lines known to produce an-
tigen (i.e., those that stimulated TNF production by M88.7
T cells after transfection with pHLA B
 
*
 
1302; see Fig. 1 A)
yielded an RT-PCR product of the size expected for the
NA88-A product. These RT-PCR products hybridized to
NA88-A cDNA (data not shown). The remaining six cell
lines known to not produce antigen (i.e., those unable to
stimulate TNF production by M88.7 T cells, even after
transfection with pHLA B
 
*
 
1302; Fig. 1 A) yielded no such
RT-PCR product (data not shown).
Using the RT-PCR approach validated by the above
results, we went on to search for NA88-A RNA in a vari- 
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ety of normal and tumor tissues. We were unable to detect
NA88-A RNA in any of the normal tissues tested, includ-
ing normal melanocytes in culture, with the possible ex-
ception of testis (only two samples were tested, though
both proved positive; data not shown). Among the tumor
samples we tested, expression of NA88-A RNA was lim-
ited to some metastatic melanomas (7 of the 66 tested; data
not shown).
 
NA88-A RNA Is Similar to the Homeoprotein-encoding
HPX42B mRNA.
 
There was no long ORF on the 2.7-
kb NA88-A cDNA, although it did contain an AATAAA
polyadenylation signal and terminal poly A tail. While the
Figure 1. Characterization of the antigen recognized by M88.7 T cells.
(A) Restriction element determination. Melanoma cell lines were tested
for their ability to induce TNF release by M88.7 T cells before (2) and
after (1) transfection with an HLAB*1302 expression vector. (B) Cloning
of the cDNA. COS-7 cells were transfected with plasmids as indicated
and tested for their ability to induce TNF release by M88.7 T cells.
Figure 2. Schematic representations of HPX42B and NA88-A se-
quences. Drawings are not to scale. (A) cDNAs; EMBL/GenBank/DDBJ
accession nos. AF164963 (NA88-A) and AF068006 (HPX42B). Homol-
ogous regions of the two cDNAs are marked in black. For HPX42B
cDNA, the open reading frame coding for the homeoprotein (ORF) and
the 39 UTR containing an Alu family member (Alu) are marked. For
NA88-A cDNA, the positions of primers used for RT-PCR are marked
(400 and 970). (B) Alignment of HPX42B and NA88-A genomic
sequences, EMBL/GenBank/DDBJ accession nos. AF164964 and
AC006177, respectively. The positions of two HPX42B gene introns are
marked, but not their sequences. Dashes represent bases missing in one of
the two sequences, and the number of bases concerned is marked. The al-
ternative 39 splice site of the HPX42B second exon is marked 39SS. For
the NA88-A sequence, the last base shown (g) corresponds to the first
base of the cloned cDNA whose sequence is represented in Fig. 2 A. (C)
Schematic alignment of the genomic sequences. For the HPX42B gene,
exons are marked as boxes, and introns separating them are shown as
lines. The alternative 39 splice site is marked 39SS. The positions of initia-
tion codons (ATG) and stop codons (*) discussed in the text and boxed in
A are marked. The NA88-A gene representation is a composite using in-
formation derived from the cosmid and the cDNA as indicated. 
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sequence was new, its first 1,048 nucleotides proved to be
 
z
 
90% identical to two noncontiguous parts (separated by
an Alu family member) of the 3
 
9
 
 untranslated region
(UTR) of the previously reported HPX42B cDNA (Fig. 2
A; similar sequences are shown in black). HPX42B cDNA
was originally obtained in a search for new homeobox
genes, using degenerate PCR on cDNA derived from a
purified population of CD34
 
1
 
 human hemopoietic cells
(20). The similarity between the NA88-A and HPX42B
sequences suggested that the cloned NA88-A cDNA could
be part of the 3
 
9
 
 UTR of a homeoprotein-encoding gene
related to HPX42B. To test this hypothesis, we decided to
isolate the genomic NA88-A gene by screening a human
cosmid library.
 
A Processed Pseudogene Encodes NA88-A RNA.
 
We iso-
lated one NA88-A cosmid and sequenced part of it to
search for sequences coding for a HPX42B-like protein.
The NA88-A sequence determined is shown in Fig. 2 B,
aligned with the corresponding HPX42B gene sequence.
(A region of chromosome 10 including the HPX42B has
been sequenced. Comparison of this sequence with the
HPX42B cDNA shows that the gene contains two introns.
Their positions, but not their sequences, are marked in Fig.
2 B.) The NA88-A and HPX42B sequences are very simi-
lar. However, relative to the 
 
HPX42B
 
 gene, the 
 
NA88-A
 
gene contains a number of mutations. One point mutation
converts codon 22 of the 
 
HPX42B
 
 gene (tgg) into a pre-
mature stop codon (tga; boxed in Fig. 2 B). Relative to the
 
HPX42B
 
 gene, the 
 
NA88-A
 
 gene also contains a number
of deletions and insertions. While several of these remove
or add codons without changing the reading frame, two of
the deletions (of 1 and 80 bp) and one insertion (of 2 bp)
do change it. As a result of all these mutations, the 
 
NA88-A
 
gene no longer codes for a homeoprotein.
Further comparison of the genes shows that the 
 
NA88-A
 
gene lacks equivalents of the HPX42B gene’s introns (Fig.
2, B and C). These observations strongly suggest that the
 
NA88-A
 
 gene is a processed pseudogene, resulting from
Figure 3. Identification of the antigenic peptide. (A) Translation products of nucleotides 674–730 of NA88-A cDNA in all three reading frames. 1, 2,
and 3: peptides synthesized. (B) Production of TNF by M88.7 T cells in response to M88 cells or one of the three synthetic peptides shown in A as
marked. (C and D) Determination of the minimal antigenic peptide. Production of TNF (C) and IL-2 (D) by the M88.7 T clone in response to different
synthetic peptides derived from peptide 1. For A, T cell clone M88.7 was stimulated with different concentrations of each peptide. For B, T cell clone
M88.7 was stimulated with 50 mM peptide. Fixed, stimulated cells were stained for cytokine and analyzed on a FACScan™. Percentages of positive cells
are indicated in the dot plots. 
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chromosomal integration of part of a retrotranscript of
HPX42B mRNA. For splicing of the first HPX42B intron,
the HPX42B mRNA employed to generate the NA88-A
gene appears to have used an alternative 3
 
9
 
 splice site (3
 
9
 
SS
in Fig. 2, B and C). We cannot tell how the second intron
was removed, as the 
 
NA88-A
 
 gene contains a large dele-
tion covering the region corresponding to the junction be-
tween HPX42B exons 2 and 3. One hallmark of processed
pseudogenes is the presence of an A-rich sequence corre-
sponding to the poly A tail of the original mRNA. How-
ever, as the 
 
NA88-A
 
 gene lacks sequences corresponding
to the end of the HPX42B mRNA’s 3
 
9
 
 UTR (Fig. 2 A),
this A-rich sequence is not expected to be present in the
NA88-A pseudogene. In conclusion, our data show that
the NA88-A antigen is coded for (a) by a processed
pseudogene and (b) by sequences derived from the 3
 
9
 
UTR of the HPX42B mRNA.
 
Identification of the Peptide Recognized by M88.7 T Cells.
 
To identify the region of the 2,729-bp NA88-A cDNA
coding for the antigenic peptide, we tested a number of
subfragments for their ability to direct antigen production.
TNF was produced by M88.7 T cells exposed to COS-7
cells cotransfected with pHLA B
 
*
 
1302 and vectors contain-
ing the NA88-A cDNA region 1–722, but not by M88.7 T
cells exposed to COS-7 cells cotransfected with pHLA
B
 
*
 
1302 and vectors containing the NA88-A cDNA region
1–700 (Fig. 3 A). These results positioned the end of the
sequence coding for the antigenic peptide between nucle-
otides 700 and 722. Peptides covering all three reading
frames encoded by the cDNA region 684–730 were syn-
thesized (Fig. 3 A) and tested for their capacity to induce
TNF production by M88.7 T cells. Only one of them led
to significant TNF production (peptide 1, RMTQGQH-
FLQKV; Fig. 3 B).
To characterize the antigenic peptide further, two 10-
mers and two 9-mers representing different but overlap-
ping regions of the 12-mer peptide 1 were tested in parallel
for their capacity to induce secretion of TNF by M88.7 T
cells (Fig. 3 C). Results obtained show (a) that removal of
the COOH-terminal valine abolishes peptide activity and
(b) that the 10-mer (TQGQHFLQKV) and the 9-mer
(QGQHFLQKV) with this valine present are both about as
active as the parent 12-mer. A similar conclusion was
reached when IL-2 production by M88.7 T cells exposed
to the peptides was measured (Fig. 3 D).
 
HPX42B mRNA Expression Does Not Lead to T Cell
Stimulation.
 
An alignment of the HPX42B and NA88-A
cDNA sequences covering the region of the NA88-A se-
quence coding for the antigenic peptide is shown in Fig. 4
A. Part of the 3
 
9
 
 UTR of the HPX42B cDNA can poten-
tially encode the peptide MTQGQHFSQKV, which dif-
fers from the NA88-A antigenic peptide by a single substi-
tution, serine (underlined) for leucine. To test if HPX42B
mRNA expression leads to stimulation of M88.7 T cells,
COS-7 cells were cotransfected with pHLAB
 
*
 
1302 and
pHPX42B (Fig. 4 B), an expression vector containing the
entire HPX42B cDNA. Transfected cells were unable to
Figure 4. Identification of differences between HPX42B and NA88-A
cDNAs important for their differential ability to generate a signal stimu-
lating TNF release by M88.7 T cells. (A) Comparison of NA88-A and
HPX42B nucleotide and encoded protein sequences in the region coding
for antigenic peptide. Potential initiation and stop codons are indicated in
bold characters. (B) Schematic representations of normal and mutated
NA88-A and HPX42B cDNA sequences. Boxes marked P code for anti-
genic peptides and are white for the NA88-A peptide and grey for the
HPX42B peptide (as marked above each box). For NA88-A Ser, a Leu
codon, CTG, has been changed to a Ser codon, TCG, within the pep-
tide-coding region. For NA88-A Trp, a stop codon tag immediately fol-
lowing the antigenic peptide’s terminal Val codon has been changed to a
Trp codon, tgg. For HPX42B Stop, a Trp codon, tgg, immediately fol-
lowing a Val codon has been changed to a stop codon, tag. (C) pcDNA3-
based plasmids containing cDNAs as described in B were cotransfected
into COS-7 cells with pHLA B*1302. The ability of transfected cells to
induce TNF release by M88.7 T cells was measured. Note that all results
shown here are from transfections carried out simultaneously in parallel,
allowing comparison of results between samples. TNF release values for
pNA88-A are higher than those shown in the separate experiment of
Figs. 1 and 3, as results depend on COS-7 cell transfection efficiencies and
the condition of the WEHI cells used for TNF assays, both of which vary
between individual experiments. 
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stimulate TNF production by M88.7 T cells (Fig. 4 C).
However, COS-7 cells cotransfected with pHLAB
 
*
 
1302
and a point-mutated NA88-A expression vector coding for
the serine-containing HPX42B peptide (pNA88-A Ser;
Fig. 4 B) did stimulate TNF production by M88.7 T cells
(Fig. 4 C), albeit less well than cells transfected with wild-
type pNA88-A. Thus, although both NA88-A RNA and
HPX42B mRNA code for a peptide capable of stimulating
M88.7 T cells, only NA88-A RNA expression leads to
peptide presentation.
 
A Stop Codon in the NA88-A Gene Is Vital for the T Cell
Response. In NA88-A RNA, the codon coding for the
COOH-terminal Val of the antigenic peptide is followed
by a stop codon, whereas in HPX42B mRNA, the corre-
sponding Val codon is followed by a Trp codon (Fig. 4 A).
This difference is important. COS-7 cells cotransfected
with pHLAB*1302 and pNA88-A Trp (Fig. 4 B), in which
the stop codon has been replaced by the Trp codon found
in HPX42B mRNA, were unable to stimulate significant
TNF production by M88.7 T cells (Fig. 4 C). However,
COS-7 cells cotransfected with pHLAB*1302 and pHPX42B
Stop (Fig. 4 B), in which the Trp codon has been mutated
to a stop codon, were able to stimulate TNF production by
M88.7 T cells (Fig. 4 C). TNF levels obtained were similar
to those obtained using pNA88-A Ser, which codes for the
same serine-containing peptide.
Discussion
The NA88-A gene is a processed pseudogene, which no
longer codes for any likely functional protein. The NA88-
A antigen is encoded by a very short ORF, which was de-
rived from part of a functional mRNA’s 39 UTR. Our
results thus extend the possible sources of tumor antigen
coding sequences to “junk” DNA and seriously raise the
possibility that any DNA sequence can lead to antigen pro-
duction, the only limitation being that it must be tran-
scribed. As is not surprising for junk DNA, transcription of
the NA88-A gene is limited. Significant expression is found
only in a fraction of metastatic melanomas. Transcription of
the gene may occur only at a late stage in melanoma, after
multiple genetic changes have accumulated facilitating ab-
errant transcription.
In contrast, the NA88-A’s “parent” gene, the HPX42B
gene, is transcribed in a variety of normal tissues (our un-
published observations). The 39 UTR of HPX42B mRNA
has codons for a peptide that can be recognized by M88.7
T cells. However, unlike for NA88-A RNA, expression of
HPX42B mRNA does not lead to T cell stimulation. One
reason is that antigenic peptides must be excised from a
precursor of 125 amino acids (which begins MTQGQHF-
SQKVWKCPEWE...; antigenic peptide in bold). Thus,
expression of a mutated HPX42B mRNA, in which the
Trp codon immediately following the peptide’s terminal
Val codon, is replaced by a stop codon, will lead to T cell
stimulation. The absence of M88.7 T cell stimulation after
wild-type HPX42B mRNA expression can be explained if
downstream flanking residues stop appropriate peptides
from being produced in quantities sufficient for presenta-
tion. Proteolytic cleavage COOH-terminal to the peptide’s
Val residue may be inefficient. Other cleavages may be fa-
vored that lead to peptides containing MTQGQHFSQKV
but that cannot be presented productively to M88.7 T
cells, due to a problem with peptide stability, TAP (trans-
porter associated with antigen processing) transport, or
MHC loading. Alternatively, the downstream residues
could provoke cleavage within the MTQGQHFSQKV se-
quence itself. In favor of these suggestions, a number of re-
ports exist (21–28) describing the influence of flanking res-
idues on epitope production and/or presentation.
None of the above problems is likely to adversely affect
production of NA88-A antigenic peptide. The peptide
MTQGQHFLQKV is the direct translation product of a
short ORF (a stop codon follows the Val codon), and anti-
genic peptides can be derived from it after at most minimal
NH2 terminal trimming. In addition to avoiding potential
problems with precursor processing (see above), the lack of
any significant processing requirement should limit the
level of transcription and translation required to produce
sufficient levels of peptide for T cell stimulation. This could
be important, as the NA88-A RNA contains no primary
ORF, but rather many short ORFs, and there is no obvi-
ous reason why the ORF coding for the antigenic peptide
should be chosen for translation rather than any of the oth-
ers. Translation of the antigenic peptide’s ORF is thus
likely to be inefficient.
In conclusion, the NA88-A gene codes for a melanoma-
specific antigen today, in large part because, during its evo-
lution, a point mutation transformed a Trp codon into a
stop codon. This significantly augmented production of an-
tigenic peptide.
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